Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $270

Deutsche Bank analyst Gregg Gilbert maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $250 to $270.